For the Inventor, By the Inventor

Enter assignee name

Ness Ziona, Israel

Mapi Pharma Ltd.

USPTO Granted Patents = 35

% Expired Patents = 17.1

EPO Patents = 18

Forward Citations = 60

Loading Chart...

Loading Chart...

11 inventors (with patents filed for the assignee):

Ehud Marom (34 out of 36 patents)

Shai Rubnov (26 out of 26 patents)

Nadav Bleich Kimelman (10 out of 10 patents)

4. Michael Mizhiritskii (9 out of 10 patents)

5. Uri Danon (3 out of 3 patents)

6. Anna Gopin (3 out of 3 patents)

7. Galina Zats (3 out of 3 patents)

8. Frida Grynspan (2 out of 3 patents)

9. Yoram Sela (2 out of 13 patents)

10. Laura Popper (2 out of 2 patents)

11. Susanna Tchilibon (1 out of 6 patents)

Core Competencies:

Glatiramer Acetate

Depot Systems

Multiple Sclerosis

Inflammatory Bowel Disease

Long Acting

Sustained Release

Pharmacologically Acceptable Salts

Microparticles

Polymorphs

Intermediate Compounds

Sublingual Delivery

Amorphous Forms

35 patents: Sort by Forward Citations

1. 12514908 - Semaglutide depot systems and use thereof (2026-01-06),

2. 12370233 - Depot systems comprising glatiramer acetate (2025-07-29),

3. 12343371 - Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate (2025-07-01),

4. 12251380 - Depot systems comprising cariprazine or salts thereof (2025-03-18),

5. RE50301 - Depot systems comprising glatiramer or pharmacologically acceptable salt thereof (2025-02-18),

6. 12161688 - Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells (2024-12-10),

7. 12097292 - Process for preparing microparticles containing glatiramer acetate (2024-09-24),

8. 11931357 - Depot systems comprising Cariprazine or salts thereof (2024-03-19),

9. 11865213 - Semaglutide depot systems and use thereof (2024-01-09),

10. RE49251 - Depot systems comprising glatiramer or pharmacologically acceptable salt thereof (2022-10-17),

11. 11471421 - Process for preparing microparticles containing glatiramer acetate (2022-10-18),

12. 11413311 - Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells (2022-08-16),

13. 11167003 - Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems (2021-11-09),

14. 11026908 - Extended release dosage forms of pregabalin (2021-06-08),

15. 10493122 - Sublingual delivery of glatiramer acetate (2019-12-03),

Company Overview

Mapi Pharma Ltd. is a biopharmaceutical company based in Ness Ziona, Israel, specializing in the development of innovative drug formulations and delivery systems. The company focuses on enhancing the therapeutic profiles of existing medications through advanced technologies, particularly in the fields of oncology and central nervous system disorders. Mapi Pharma aims to improve patient outcomes by addressing unmet medical needs with its proprietary formulations and is committed to advancing healthcare through its research initiatives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

35 Patents

#3 in Ness Ziona

#156 in Israel

#19,168 in the World

Ness Ziona, Israel

Mapi Pharma Ltd.

Forward Citations = 60

11 inventors:

Ehud Marom (34 out of 36 patents)

Shai Rubnov (26 out of 26 patents)

Nadav Bleich Kimelman (10 out of 10 patents)

4. Michael Mizhiritskii (9 out of 10 patents)

5. Uri Danon (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mapi Pharma Ltd.. Retrieved from https://idiyas.com/company/mapi-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…